A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach.
Dipanjan KaratiDileep KumarPublished in: Current pharmaceutical design (2023)
Cancer is one of life's most difficult difficulties and a severe health risk everywhere. Except for haematological malignancies, it is characterized by unchecked cell growth and a lack of cell death, which results in an aberrant tissue mass or tumour. Vascularization promotes tumor growth, which eventually aids metastasis and migration to other parts of the body, ultimately resulting in death. The genetic material of the cells is harmed or mutated by environmental or inherited influences, which results in cancer. Presently, anti-neoplastic medications (chemotherapy, hormone, and biological therapies) are the treatment of choice for metastatic cancers, whilst surgery and radiotherapy are the mainstays for local and non-metastatic tumors. Regrettably, chemotherapy disturbs healthy cells with rapid proliferation, such as those in the gastrointestinal tract and hair follicles, leading to the typical side effects of chemotherapy. Finding new, efficient, targeted therapies based on modifications in the molecular biology of tumor cells is essential because current chemotherapeutic medications are harmful and can cause the development of multidrug resistance. These new targeted therapies, which are gaining popularity as demonstrated by the FDA-approved targeted cancer drugs in recent years, enter molecules directly into tumor cells, diminishing the adverse reactions. A form of cancer treatment known as targeted therapy goes after the proteins that regulate how cancer cells proliferate, divide, and disseminate. Most patients with specific cancers, such as chronic myelogenous leukemia (commonly known as CML), will have a target for a particular medicine, allowing them to be treated with that drug. Nonetheless, the tumor must typically be examined to determine whether it includes drug targets.
Keyphrases
- papillary thyroid
- cancer therapy
- cell death
- induced apoptosis
- locally advanced
- health risk
- cell cycle arrest
- squamous cell carcinoma
- squamous cell
- small cell lung cancer
- drug delivery
- childhood cancer
- early stage
- lymph node metastasis
- acute myeloid leukemia
- adverse drug
- early onset
- percutaneous coronary intervention
- coronary artery disease
- bone marrow
- coronary artery bypass